| Sep 3 |
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
|
| Sep 3 |
AI specialist Recursion says lead drug is safe, but efficacy less clear
|
| Aug 30 |
Is Recursion Pharmaceuticals a Warren Buffett Stock?
|
| Aug 28 |
Recursion Pharmaceuticals Inc. (RXRX): Among The Best Medical AI Companies
|
| Aug 18 |
The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.
|
| Aug 16 |
These Stocks in Nvidia's Portfolio Took a Hit in the Second Quarter
|
| Aug 13 |
Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks
|
| Aug 12 |
Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move
|
| Aug 11 |
Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?
|
| Aug 9 |
Recursion Pharmaceuticals, Inc. (RXRX) Q2 2024 Earnings Call Transcript
|
